TIAP FEATURES: Zucara Therapeutics – Building on Canada’s Rich Research History to Dramatically Change Diabetes Disease Management “I think people know quite a bit about high blood sugar and the…
Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies November 30, 2023 08:00 AM Eastern Standard Time TORONTO & WALTHAM, Mass.--(BUSINESS WIRE)--Phenomic AI Inc. (“Phenomic”), a…
TIAP and PRiME collaborate to accelerate next generation precision medicine ventures in Toronto TIAP and PRiME Next Generation Precision Medicine (PRiME) are pleased to announce their strategic partnership aimed at…
Phenomic Enters Strategic Collaboration with Boehringer Ingelheim to Discover Novel Targets for Stroma-Rich Cancer Therapies - Agreement includes licensing options based on targets to be identified with Phenomic’s unique discovery…
AmacaThera Closes Series A Extension to Advance Clinical Development of Long Acting, Localized, Non-Opioid Therapeutics to Improve Post-Surgery Patient Care November 28th, 2023 Press Release Toronto, ON — AmacaThera, a leader in the development…
The NHS East Genomic Medicine Service Alliance Harnesses PhenoTips’ Genomic Health Record in a Milestone Regional Transformation Project November 15, 2023 Toronto, ON, Canada: The NHS’ East Genomic Medicine Service…
Vasomune and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study Vasomune Therapeutics and AnGes drug candidate AV-001 Receives Positive Recommendation from the…
The Phase 2a "ZONE" study will evaluate the effect of ZT-01 on preventing nighttime hypoglycemia (low blood glucose) in people with Type 1 diabetes. Results of the Phase 1b proof-of-concept study were…
TIAP announced today the significant expansion of its flagship LAB150 drug discovery and development program with the addition of Amgen as a strategic and financial partner. Read full press release: https://bwnews.pr/3D3DUXb…
TIAP portfolio company Zucara Therapeutics moves their lead program targeting diabetes into Phase II clinical trials. Read more here. Why this news is important: Zucara has achieved the development milestones…
Schwartz Reisman Innovation Campus, West Tower
108 College Street, Suite 530
Toronto, ON M5G 0C6
info@tiap.ca